New publication in the American Journal of Sports Medicine, co-authored by TAmiRNA

Retears remain a common complication after arthroscopic rotator cuff repair. A recent study by researchers from the AUVA Trauma Center Vienna-Meidling, the Ludwig Boltzmann Institute for Traumatology, the Austrian Cluster for Tissue Regeneration, and TAmiRNA now sheds light on the molecular mechanism behind a promising augmentation strategy: a single intraoperative dose of zoledronic acid.

Background: A prior trial showed that a single systemic dose of zoledronic acid reduces retear rates in non-osteoporotic patients after rotator cuff repair. This follow-up study investigated the underlying biology by profiling circulating miRNAs linked to inflammation, fibrosis, and tendon-to-bone healing.

Design: In a single-center, randomized, placebo-controlled, triple-blinded phase II trial, 80 patients were assigned intraoperatively to zoledronic acid (n=40) or control (n=40). Plasma miRNAs were measured before surgery, at day 2, and at 3 months using small RNA sequencing and RT-qPCR.

Key findings: Six miRNAs were validated by RT-qPCR. No baseline differences were seen between groups. Two days post-surgery, miR-140-3p was significantly lower in the zoledronic acid group, while the control group showed significant drops in four miRNAs (miR-29a-3p, miR-21-5p, miR-192-5p, miR-146a-5p). By 3 months, profiles had converged. Target gene analysis pointed to collagen I and III, VEGF, IGF-1, and TGF-β1 — key drivers of collagen synthesis, vascularization, and fibrosis control.

Takeaway: The distinct miRNA trajectories suggest zoledronic acid dampens inflammation and fibrosis at the enthesis while promoting collagen synthesis and vascularization — offering a plausible molecular explanation for the previously observed clinical benefit. The authors note that zoledronic acid is a safe, easy-to-apply augmentation technique for rotator cuff repair.

This work builds on TAmiRNA’s ongoing collaboration with AUVA Trauma Center Vienna-Meidling and the Ludwig Boltzmann Institute, and further highlights the value of circulating miRNAs as non-invasive biomarkers of musculoskeletal healing.